Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Akero Therapeutics Is Surging Today

By Cory Renauer - Mar 31, 2020 at 2:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A first-in-class new drug candidate for the treatment of non-alcoholic steatohepatitis produced some compelling clinical trial results.

What happened

Shares of Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biopharmaceutical company, are on the move after the company's lead candidate succeeded in a controlled clinical trial. Investors impressed with the results have pushed the stock 22% higher as of 1:36 p.m. EDT on Tuesday.

So what 

Non-alcoholic steatohepatitis (NASH) is a potentially fatal condition caused by inflammation of a fatty liver. Around a quarter of adults in the U.S. have livers with dangerously high fat levels and around a fifth of this group progress to NASH. Since there aren't any available treatment options, Akero's lead candidate could generate blockbuster sales if it continues to succeed. 

Upward sloping chart drawn by a finger.

Image source: Getty Images.

During a placebo-controlled dose-determination study with 80 NASH patients, every group treated with Akero Therapeutics' lead candidate AKR-001 showed significant improvements compared to the placebo group. Investors were especially encouraged by significant improvements among patients in the group receiving the lowest dose.

Now what

Akero's NASH candidate could be the first drug of its type to earn approval, but it's going to need clinical trial results from a lot more patients before it has enough evidence to support a new drug application.

Patients treated with AKR-001 had significantly less fat in their liver measured by MRI, and fewer signs of liver damage in their bloodstream after 12 weeks. Investigators are still taking liver biopsies from patients who achieved a 30% liver fat reduction or better, which the company intends to share in the second quarter.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.